EXUMA Biotech
EXUMA’s GCAR platform combines CD3-targeted lentiviral delivery with FITNESS DRIVER for in vivo CAR engineering. Its separate rPOC SC platform incubates PBMCs with vector outside the body and should not be described as fully in vivo manufacturing. Current GCAR clinical stage was not verified.
Corporate information
- Company entity
- EXUMA Biotech
- Headquarters / principal office
- West Palm Beach, FLSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2015 ↗
- Ownership / capital status
- PrivatePrivately held biotechnology company ↗
- Official corporate reference
- https://exumabio.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
EXUMA’s GCAR platform combines CD3-targeted lentiviral delivery with FITNESS DRIVER for in vivo CAR engineering. Its separate rPOC SC platform incubates PBMCs with vector outside the body and should not be described as fully in vivo manufacturing. Current GCAR clinical stage was not verified.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- EXUMA Biotech — primary program / ownership disclosure
- EXUMA Biotech — official company page
- EXUMA company formation and identity disclosure
- Company-managed LinkedIn profile — self-reported location